Journal of Nanomedicine & Nanotechnology

Tailored design strategy for improved clinical translation of anticancer nanomedicines

7^th International Conference on Nanomedicine And Nanotechnology

June 28, 2023 | Webinar

Wei Gao

University of Michigan, USA

Posters & Accepted Abstracts: J Nanomed Nanotechnol

Abstract:

The low success rate of anticancer nanomedicines has prompted discussions on design criteria, with a focus on long-circulating nanomedicines that target tumors and avoid normal tissue accumulation through the EPR effect. However, after comprehensively analyzing the delivery of clinically approved nanomedicines in tumor and normal tissues in three preclinical cancer models, we have concluded that nanoparticles cannot generally enhance tumor distribution and decrease healthy tissue distribution. Instead, they exhibit a drug- and material-specific distribution in different tissue and cell types (1). To address this issue, we propose a tailored anticancer nanomedicine design strategy that is cancer-type specific, cell-type specific, drug-specific, and nanocarrier-specific (2). Using this new design criteria, we have developed a nanomedicine called Nano-PI, which overcame the limitation of low accumulation of IPI-549 and PTX in the macrophages of lymph nodes and tumors by utilizing albumin nanoparticles to deliver drugs into these two tissues. Specifically, Nano-PI was able to target M2 macrophages, which are one of the major immunosuppressive factors in metastatic breast cancer. This nanoparticle design achieved long-term tumor remission in mouse models and eliminated lung metastases, making it a promising candidate for future clinical trials (3). In general, our study provides a tailored anticancer nanomedicine design strategy that is cancer-type specific, cell-type specific, drug-specific, and nanocarrier-specific. This new designed strategy may improve success rates in clinical cancer patients.